SCHEMBL3757815

SCHEMBL3757815

O=c1c(O)c(-c2ccc(O)c(OCP(=O)(O)O)c2)oc2ccccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.62
MEN1 O00255 10/20 0.62
CYP3A4 P08684 10/20 0.62
KMT2A Q03164 10/20 0.62
TP53 P04637 9/20 0.62
MAPT P10636 8/20 0.62
HSD17B10 Q99714 8/20 0.62
MAPK1 P28482 6/20 0.62
ALOX15 P16050 6/20 0.62
ALOX12 P18054 5/20 0.62
CYP2C9 P11712 4/20 0.62
CYP2D6 P10635 3/20 0.62
CYP2C19 P33261 3/20 0.62
CDK2 P24941 2/20 0.62
RECQL P46063 2/20 0.62
ST6GAL1 P15907 1/20 0.62
RXFP1 Q9HBX9 1/20 0.62
ALDH1A1 P00352 7/20 0.60
HPGD P15428 7/20 0.60
LMNA P02545 5/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3715897 0.88 MEN1 (0.69) KDM4EMEN1CYP3A4KMT2ATP53
SCHEMBL3754134 0.82 KDM4E (0.62) KDM4EMEN1CYP3A4KMT2ATP53
SCHEMBL3755551 0.81 MEN1 (0.69) KDM4EMEN1CYP3A4KMT2ATP53
SCHEMBL15844041 0.81 KDM4E (0.83) KDM4EMEN1CYP3A4KMT2ATP53
SCHEMBL13056266 0.79 MAPT (0.63) KDM4EMEN1CYP3A4KMT2ATP53
SCHEMBL13056280 0.79 MEN1 (0.52) KDM4EMEN1CYP3A4KMT2AMAPT
SCHEMBL15676575 0.78 MEN1 (1.00) KDM4EMEN1CYP3A4KMT2ATP53
SCHEMBL30626973 0.78 MEN1 (1.00) KDM4EMEN1CYP3A4KMT2ATP53
SCHEMBL29437764 0.78 MEN1 (1.00) KDM4EMEN1CYP3A4KMT2ATP53
SCHEMBL169366 0.78 MEN1 (1.00) KDM4EMEN1CYP3A4KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297020-A1 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT LIMERICK BIOPHARMA, INC. (US) 2010-11-25 US disclosed
US-20100297020-A1 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT LIMERICK BIOPHARMA, INC. (US) 2010-11-25 US disclosed
US-20100297020-A1 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT LIMERICK BIOPHARMA, INC. (US) 2010-11-25 US disclosed
WO-2010129138-A2 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT LIMERICK BIOPHARMA (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297020-A1 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT PC, PCK1, PYGL KDM4E 3745/4885MEN1 2302/4885CYP3A4 2300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.